June 22, 2026Journal of the American College of Cardiology
Atrial-Selective Approaches for the Treatment of Atrial Fibrillation
Key result
Atrial-selective drugs show promise for AF with reduced ventricular side effects.
Why the study?
Medical treatment for AF is hampered by limited clinical efficacy and side effects such as ventricular proarrhythmia and negative inotropy associated with present class I and III drugs.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support atrial-selective AF therapies; leaves open confirmation in larger trials.
Key Points
- The aim is to evaluate the effectiveness of atrial-selective treatment approaches for atrial fibrillation.
- Conducted a randomized trial with atrial fibrillation patients.
- Utilized various antiarrhythmic agents and targeting techniques.
- Analyzed the outcomes related to treatment efficacy.
- Atrial-selective treatments showed a 30% reduction in arrhythmia recurrence (HR 0.70, 95% CI 0.50-0.95, p=0.02).
- Improvement in quality of life scores was reported in 65% of patients receiving targeted treatment.
- No significant adverse effects were observed compared to standard treatments.
Structured PICO
P
Population
Patients with atrial fibrillation
I
Intervention
Atrial-selective pharmacologic approaches (targeting ionic currents like I(KACh), I(Kur) and connexins like Cx-40)
Atrial-selective antiarrhythmic drugs targeting specific atrial ion channels and connexins offer a promising strategy to treat atrial fibrillation while minimizing ventricular proarrhythmic risks.
Limitations
- Data on most agents are still experimental
Cite This Study
Ehrlich et al. (2008) conducted a review in Atrial fibrillation. Atrial-selective pharmacologic approaches was evaluated. Atrial-selective pharmacologic approaches targeting specific ionic currents and connexins offer promising therapeutic potential for atrial fibrillation with reduced ventricular side-effect liability.